ReviewCancer gene therapy2018
CRISPR/Cas9 genome editing technology significantly accelerated herpes simplex virus research.
Review in Cancer gene therapy, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 51 citations in OpenAlex.
- Antiviral activity of nitazoxanide against pseudorabies virus infectionFrontiers in veterinary science · 2025Article
- A review of HSV pathogenesis, vaccine development, and advanced applications.Molecular biomedicine · 2024Review
- Detection and Genomic Characterization of Torque Teno Virus in Pneumoconiosis Patients in China.Viruses · 2024Article
- Innovative stain-free technique for high-resolution imaging of virus particles via standard transmission electron microscopy.Heliyon · 2024Article
- Hemophilia Healing with AAV: Navigating the Frontier of Gene Therapy.Current gene therapy · 2024Review
- The iron group transition-metal (Fe, Ru, Os) coordination of Se-doped graphitic carbon (Se@g-CRSC advances · 2023Article
- High-throughput engineering of cytoplasmic- and nuclear-replicating large dsDNA viruses by CRISPR/Cas9.The Journal of general virology · 2022Article
- Oncolytic viral vectors in the era of diversified cancer therapy: from preclinical to clinical.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2022Review
- Methods for the Manipulation of Herpesvirus Genome and the Application to Marek's Disease Virus Research.Microorganisms · 2021Review
- Review
- Bispecific T cell engagers and their synergistic tumor immunotherapy with oncolytic viruses.American journal of cancer research · 2021Review
- Mechanisms and Clinical Trials of Hepatocellular Carcinoma Immunotherapy.Frontiers in genetics · 2021Review
- A Generally Applicable CRISPR/Cas9 Screening Technique to Identify Host Genes Required for Virus Infection as Applied to Human Cytomegalovirus (HCMV) Infection of Epithelial Cells.Methods in molecular biology (Clifton, N.J.) · 2021Article
- Human Cytomegalovirus miR-US33as-5p Targets IFNAR1 to Achieve Immune Evasion During Both Lytic and Latent Infection.Frontiers in immunology · 2021Article
- The old CEACAMs find their new role in tumor immunotherapy.Investigational new drugs · 2020Review
- High-efficiency nonhomologous insertion of a foreign gene into the herpes simplex virus genome.The Journal of general virology · 2020Article
- Dendritic cell biology and its role in tumor immunotherapy.Journal of hematology & oncology · 2020Review
- Novel transcription regulatory sequences and factors of the immune evasion protein ICP47 (US12) of herpes simplex viruses.Virology journal · 2020Article
- Developing oncolyticIranian journal of basic medical sciences · 2020Article
- CRISPR-Cas genome editing tool: a narrow lane of cancer therapeutics with potential blockades.Translational cancer research · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 5 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Herpes simplex viruses (HSVs) are important pathogens and ideal for gene therapy due to its large genome size. Previous researches on HSVs were hampered because the technology to construct recombinant HSVs were based on DNA homology-dependent repair (HDR) and plaque assay, which are inefficient, laborious, and time-consuming. Fortunately, clustered regularly interspaced short palindromic repeat/CRISPR-associated protein 9 (CRISPR/Cas9) recently provided the possibility to precisely, efficiently, and rapidly edit genomes and indeed is successfully being used in HSVs. Importantly, CRISPR/Cas9 technology increased HSV HDR efficiency exponentially by a 10,000-1,000,000 times when making recombinant HSVs, and its combination with flow cytometric technology made HSV recombination practically automatic. These may have a significant impact on virus and gene therapy researches. This review will summarize the latest development and molecular mechanisms of CRISPR/Cas9 genome editing technology and its recent application in HSVs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.